利咽口服液对实验性慢性咽炎病理形态学的影响

目的：观察利咽口服液对慢性咽炎动物模型咽部病理形态的影响。方法：采用光镜对利咽口服液高、中、低治疗组及模型组、阳性对照组动物的咽部组织进行了观察。结果：模型动物咽部上皮内可见灶性或弥漫性炎细胞浸润(主要为淋巴细胞、单核细胞)；上皮层轻度增厚，钉突延长，血管明显扩张、充血、纤维组织增生；经利咽口服液治疗，动物咽部的慢性炎症明显减轻或趋于正常，且以中、高剂量组为明显。结论：利咽口服液对慢性咽炎有较好的治疗作用。其作用可能是通过抗炎、改善咽部血管通透性、减轻炎性渗出、抑制组织增生等多途径来实现的。     

贞芪扶正口服液的质量标准

目的制订贞芪扶正口服液质量标准。方法用薄层色谱法鉴别黄芪、女贞子、白术 ;用香草醛 硫酸比色法测定黄芪甲苷的含量。结果平均回收率为 98 95 % ,RSD为 0 81 % (n =5 )。结论建立的方法可控制贞芪扶正口服液的质量     

Implication of brevetoxin B1 and PbTx-3 in neurotoxic shellfish poisoning in New Zealand by isolation and quantitative determination with liquid chromatography-tandem mass spectrometry.

Brevetoxin B1 (BTX-B1) was isolated from Austrovenus stutchburyi following the 1992-1993 outbreak of neurotoxic shellfish poisoning (NSP) in New Zealand. We report here the first isolation of PbTx-3 from the same shellfish and the development of a procedure for quantitative determination of PbTx-3 and BTX-B1. PbTx-3 was isolated by chromatography on columns of SiO2, ODS, and LH-20, followed by reverse-phase HPLCs. In mass spectrometry (MS) with an electrospray ionization (ESI) interface operating in the positive or negative ion mode, the abundant protonated ion [M+H]+ of PbTx-3 (m/z 897) and the de-sodiated ion [M-Na]- of BTX-B1 (m/z 1016) were generated, respectively. These served as precursor ions for collision-induced dissociation, and the product ions of m/z 725 from PbTx-3 and m/z 80 from BTX-B1 were identified, allowing unambiguous confirmation of these toxins by selected reaction monitoring liquid chromatography-tandem mass spectrometry (SRM LC-MS/MS) analysis. The determination limits were 0.4 and 2 ng/g for BTX-B1 and PbTx-3 at a signal-to-noise ratio of five, respectively. This LC-MS/MS method was successfully applied to determine BTX-B1 and PbTx-3 in the NSP-associated toxic shellfish. BTX-B1 was found in both A. stutchburyi and Perna canaliculus, but not in Crassostrea gigas, while PbTx-3 was found in all three.     

抗癌口服液在体内外抗肿瘤作用的实验研究

OBJECTIVETo investigate anti-cancer of the Anti-cancer Oral Liquid (ACOL) for MGC-803 gastric cancer cell line in vivo and vitro. METHODUsing the MTT assay, colonogenic assay and sero-pharmacological experiment by treating with the Chinese traditional med     

HPLC-MS法测定犬血浆中环维黄杨星D浓度及其药代动力学研究

目的 :建立用于测定环维黄杨星D血药浓度的液相色谱 质谱联用分析方法 ,并探讨环维黄杨星D在犬体内的药代动力学。方法 :犬 5只ig环维黄杨星D 10mg·kg-1后采集一系列血样 ,利用HPLC MS(TOF)法 ,测定血浆药物浓度 ,并用 3p97软件拟合求算药代动力学参数。结果 :环维黄杨星D浓度在 0 5～ 2 0 0ng·ml-1线性关系良好 (r=0 9999)。提取回收率高于 80 % ,日内、日间RSD均小于 15 % ,符合生物样品分析要求。 5只犬ig环维黄杨星D 10mg·kg-1后的血药浓度 时间曲线呈二室模型 ,其吸收相、分布相和末端消除相的半衰期 (t1/ 2Ka、t1/ 2α和t1/ 2 β)分别为 1 72 ,2 82 ,14 90h ,曲线下面积 (AUC)为 1372 5± 2 19 4ng·h·ml-1。结论 :建立的HPLC MS联用方法专属性强 ,灵敏度高 ,可用于环维黄杨星D的体内定量分析。     

吸液态氧对高原移居青年肺通气功能的影响

目的　探讨在高原地区吸入液态氧对移居青年肺通气功能的影响。　方法　将进驻海拔 370 0m半年的 4 0名健康青年随机分为两组 ,每组 2 0人。一组为对照组 ,受试者用EGM型踏车功量计做坐位踏车运动 ,初始负荷功率 2 5W ,每 3min递增 5 0W ,以 6 0rpm/min连续踏车直至力竭。另一组为实验组 ,在运动前10min开始用面罩吸液态氧 ,每min吸入量为 4L ,在踏车运动中全程吸氧 ,踏车方式同对照组。计算每位受试者运动功率 2 2 5W时的每分钟肺通气量 (VE)。　结果　吸氧组和对照组VE 分别为 32 16± 3 6 2与 38 78± 2 2 3;血氧饱和度 (SaO2 )分别为 84 10± 4 2 2与 73 70± 2 34。VE 明显降低 ,SaO2 明显增高 ,差异非常显著(P <0 0 1)。　结论　吸液态氧能明显改善高原移居青年的肺通气量并提高做功效率。     

DABS-CI柱前衍生RP-HPLC法定量测定生理样本氨基酸

目的:DABS-C1柱前衍生RP-HPLC法定量测定生理样本中的氨基酸。方法:采用DABS-C1柱前衍生RP-HPLC法,在紫外436nm处测定氨基酸。结果:人血清、脑脊液(CSF)和细胞培养液中的氨基酸在60min中得到良好的分离和测定。结论:DABS-C1柱前衍生RP-HPLC定量分析生理样本中的氨基酸,具有较好精准性,是一种比较疗便、稳定和可靠的检测方法。     

生命1号健脑强身及促骨生长的实验研究

采用水迷宫法、穿梭箱法、避暗法、跳台法观察了生命1号对小鼠学习、记忆、巩固的影响。灌胃给生命1号可改善东莨菪碱、樟柳碱致小鼠记忆获得障碍。生命1号能明显提高单核细胞吞噬功能，显著增加小鼠血清溶血素的含量，促进T淋巴细胞的转化。除此之外，还能明显地增加阳虚大鼠股骨的重量、长度、直径及皮质厚度；提高血清钙、磷水平；降低血清碱性磷酸酶的含量，具有促进骨骼生长的作用。     

Quantitation of dolastatin-10 using HPLC/electrospray ionization mass spectrometry: application in a phase I clinical trial

A highly sensitive and specific assay for the quantitation of the anticancer agent dolastatin-10 (DOL-10) in human plasma is described. The method was based on the use of electrospray ionization-high-performance liquid chromatography/mass spectrometry (ESP-LC/MS). The analytical procedure involved extraction of plasma samples containing DOL-10 and the internal standard (DOL-15) with n-butyl chloride, which was then evaporated under nitrogen. The residue was dissolved in 50 μl mobile phase and 10 μl was subjected to ESP-LC/MS analysis using a C₁₈ microbore column. A linear gradient using water/acetonitrile was used to keep the retention times of the analytes of interest under 5 min. The method exhibited a linear range from 0.005 to 50 ng/ml with a lower limit of quantitation (LLQ) at 0.005 ng/ml. Absolute recoveries of extracted samples in the 85–90% range were obtained. The method's accuracy (≤5% relative error) and precision (≤10% CV) were well within industry standards. The analytical procedure was applied to extract DOL-10 metabolites from samples obtained following incubation of the drug with an activated S9 rat liver preparation. Two metabolic products were detected and were tentatively identified as a N-demethyl-DOL-10 and hydroxy-DOL-10. Structural assignments were made based on the fragmentation patterns obtained using the electrospray source to produce collision-induced dissociation (CID). The method was also applied to the measurement of DOL-10 in the plasma of patients treated with this drug. Preliminary investigation of the pharmacokinetics suggested that drug distribution and elimination may be best described by a three-compartment model with t_1/2α = 0.087 h, t_1/2β = 0.69 h and t_1/2γ = 8.0 h. Plasma clearance was 3.7 l/h per m². Received: 17 March 1997 / Accepted: 13 June 1997     

通脉降脂口服液防治冠状动脉粥样硬化性心脏病的临床观察

目的：观察中药复方通脉降脂口服液降低血脂、减轻自由基损伤、调整前列腺素代谢、治疗冠心病心能的临床疗效。方法：治疗组４１例、对照组２４例冠心病心纹痛伴高脂血症患者分别口服通脉降脂口服液及月见草油胶丸各１个月，进行临床人作对比并观察治疗前后血脂、载脂蛋白（ａｐｏ）、血浆丙二醛（ＭＤＡ）、全血谷胱甘肽过氧化物酶（ＧＳＨ－Ｐｘ）、血栓素Ｂ２（ＴＸＢ２）、６－酮－前列腺素Ｆ１α（６－－ＰＧＦ１α）等的变化。